Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, DoubleâBlind, Phase 3 Trials
Authors: Bissonnette R, Albreiki F, Ehst BD, Hammadi AA, Schliemann S, Yang B, Zhang J, Bunick CG Read more on pubmed
Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia
Authors: Martin A, Shokrian N, Kelley KJ, Correa da Rosa J, Del-Duca E, Bissonnette R, Sorensen OE, Nielsen AB, Guttman-Yassky E, Makredes Senna M Read more on pubmed
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial.
Authors: Bissonnette R, Vender R, Pinter A, Stanley LM, Houts CR, Miller M, DeLozier AM, Li S, Iaconangelo C, Ferris LK. Read more on pubmed
Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema.
Authors:Thaçi D, Gooderham M, Lovato P, Madsen DE, Soehoel A, Bissonnette R. Read more on pubmed
Tissue-Resident Memory and Follicular/Peripheral Helper PD-1+ T Cells Infiltrate Lesional Skin in Atopic Dermatitis.
Authors: Mehta H, Pellerin L, Rubio M, Maari C, Proulx ĂS, Nischal S, Moulton VR, Leung MWL, Bissonnette R, Sarfati M. Eur Read more on pubmed
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.
Authors: Simpson EL, Silverberg JI, Bissonnette R, Stein Gold L, Armstrong A, Hebert AA, Serrao RT, Jakus JR, Brown PM, Rubenstein DS, Piscitelli SC, Tallman AM, Eichenfield LF. Read more on pubmed
Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis.
Authors: Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI. Read more on pubmed
Reflections on chronic hand eczema – Authors’ reply.
Authors: Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S. Read more on pubmed
Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.
Authors:Â Sachen KL, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard KL, Manieri NA, Bao P, Greving C, Lacy ER, DuPrie M, Wertheimer J, Deming JD, Brown J, Hart A, Li HH, Freeman TC, Keyes B, Kohler K, White I, Karpowich N, Steele R, Elloso MM, Fakharzadeh S, Goyal K, Lavie F, Abreu MT, Allez […]
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials
Authors: Gooderham M, Molin S, Bissonnette R, Worm M, Crépy MN, Stingeni L, Warren RB, Schliemann S, Schuttelaar ML, Ferrucci S, Serra-Baldrich E, Silverberg JI, Balita-Crisostomo CL, Oesterdal ML, Plohberger U, Agner T. Read more on pubmed
